35 results
Thumbnail

D1.216 - From Acetaminophen to sauerkraut

Thumbnail

D1.217 - Rapid drug desensitization in children: case report

Thumbnail

D1.219 - Impact of a Penicillin Allergy Delabeling Program on Antibiotic Selection and Perioperative Outcomes: A Prospective Comparative Cohort Study

Thumbnail

D1.222 - Comparative analysis and evaluation of clinical and stewardship implications of parent reported antibiotic allergy labels within paediatric care

Thumbnail

D1.223 - Evaluation of Immediate-Type Allergic Reactions to Amide Group Local Anesthetics In Children: A Single-Center

Thumbnail

D1.224 - Clinical performance of IgE Quaternary Ammoniums, Atracurium, Rocuronium and Suxamethonium for the diagnosis of an allergy to curares

Thumbnail

D1.225 - Direct single dose mass delabelling of antibiotic allergy in paediatrics

Thumbnail

D1.226 - Increased incidence of suspected clindamycin hypersensitivity reactions in pediatric patients due to its expanded use in clinical practice

Thumbnail

D1.227 - Risk stratification of drug allergy in children with immediate or delayed urticaria during antibiotic treatment

Thumbnail

D1.228 - Patch testing and HLA genotyping as diagnostic tools for DRESS related to concomitant multidrug exposure

Thumbnail

D1.229 - Limited interest of suxamethonium, rocuronium and atracurium specific IgE reagents for the diagnosis of NMBA allergy sensitization

Thumbnail

D1.230 - Acute Localized Exanthemathous pustulosis induced by Pertuzumab and Trastuzumab with positive Lymphocyte Transformation test

Thumbnail

D1.231 - When Antihistamines Paradoxically Worsen Chronic Spontaneous Urticaria: Trust Your Patient

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results